Mereo BioPharma (MREO) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.30, -1.94% vs the prior close of $0.31.
- Volume 720.54K shares, 0.1x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
MREO dips 1.9% to $0.30, 3 down days in a row. Closed at $0.30, -1.94% vs the prior close of $0.31. Day range $0.29–$0.31, opened at $0.30.
MREO daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — MREO dips 1.9% to $0.30, 3 down days in a row
- Closed at $0.30, -1.94% vs the prior close of $0.31. Day range $0.29–$0.31, opened at $0.30.
- Volume was 720.54K shares, 0.1x its 50-day average of 4.91M — lighter than usual.
- Price is -1.6% vs its 50-day average ($0.31) and -11.9% vs its 200-day average ($0.34).
- 52-week range $0.20–$2.37; today's close sits at 5% of that range, 87.2% below the 52-week high.
- That makes 3 straight losses.
Oct 15, 2026 — MREO dips 0.3% to $0.31
- Closed at $0.31, -0.32% vs the prior close of $0.31. Day range $0.30–$0.32, opened at $0.30.
- Volume was 512.60K shares, 0.1x its 50-day average of 4.92M — lighter than usual.
- Price is +0.3% vs its 50-day average ($0.31) and -10.2% vs its 200-day average ($0.34).
- 52-week range $0.20–$2.37; today's close sits at 5% of that range, 87.0% below the 52-week high.
Oct 14, 2026 — MREO slides 3.1% to $0.31
- Closed at $0.31, -3.12% vs the prior close of $0.32. Day range $0.30–$0.32, opened at $0.31.
- Volume was 890.20K shares, 0.2x its 50-day average of 4.91M — lighter than usual.
- Price is +0.7% vs its 50-day average ($0.31) and -9.9% vs its 200-day average ($0.34).
- 52-week range $0.20–$2.37; today's close sits at 5% of that range, 86.9% below the 52-week high.
Oct 13, 2026 — MREO rises 1.6% to $0.32
- Closed at $0.32, +1.59% vs the prior close of $0.31. Day range $0.30–$0.32, opened at $0.31.
- Volume was 1.27M shares, 0.3x its 50-day average of 4.90M — lighter than usual.
- Price is +3.9% vs its 50-day average ($0.31) and -9.6% vs its 200-day average ($0.35).
- 52-week range $0.20–$2.37; today's close sits at 6% of that range, 86.5% below the 52-week high.
Oct 12, 2026 — MREO slides 10.0% to $0.31
- Closed at $0.31, -10.00% vs the prior close of $0.35. Day range $0.31–$0.36, opened at $0.35.
- Volume was 1.33M shares, 0.3x its 50-day average of 4.93M — lighter than usual.
- Price is +2.3% vs its 50-day average ($0.31) and -13.5% vs its 200-day average ($0.36).
- 52-week range $0.20–$2.37; today's close sits at 5% of that range, 86.7% below the 52-week high.
Oct 9, 2026 — MREO slides 6.7% to $0.35
- Closed at $0.35, -6.67% vs the prior close of $0.38. Day range $0.34–$0.39, opened at $0.38.
- Volume was 1.22M shares, 0.2x its 50-day average of 4.92M — lighter than usual.
- Price is +13.4% vs its 50-day average ($0.31) and -6.4% vs its 200-day average ($0.37).
- 52-week range $0.20–$2.37; today's close sits at 7% of that range, 85.2% below the 52-week high.
Oct 8, 2026 — MREO jumps 6.2% to $0.38
- Closed at $0.38, +6.23% vs the prior close of $0.35. Day range $0.34–$0.38, opened at $0.35.
- Volume was 1.06M shares, 0.2x its 50-day average of 4.93M — lighter than usual.
- Price is +21.8% vs its 50-day average ($0.31) and -2.2% vs its 200-day average ($0.38).
- 52-week range $0.20–$2.37; today's close sits at 8% of that range, 84.2% below the 52-week high.
Oct 7, 2026 — MREO rises 0.9% to $0.35
- Closed at $0.35, +0.86% vs the prior close of $0.35. Day range $0.35–$0.37, opened at $0.35.
- Volume was 1.13M shares, 0.2x its 50-day average of 4.94M — lighter than usual.
- Price is +15.2% vs its 50-day average ($0.31) and -9.9% vs its 200-day average ($0.39).
- 52-week range $0.20–$2.37; today's close sits at 7% of that range, 85.1% below the 52-week high.
Oct 6, 2026 — MREO slides 9.8% to $0.35
- Closed at $0.35, -9.79% vs the prior close of $0.39. Day range $0.35–$0.40, opened at $0.40.
- Volume was 1.27M shares, 0.3x its 50-day average of 4.94M — lighter than usual.
- Price is +14.5% vs its 50-day average ($0.31) and -12.4% vs its 200-day average ($0.40).
- 52-week range $0.20–$2.37; today's close sits at 7% of that range, 85.2% below the 52-week high.
Oct 5, 2026 — MREO rises 2.1% to $0.39
- Closed at $0.39, +2.11% vs the prior close of $0.38. Day range $0.36–$0.40, opened at $0.37.
- Volume was 2.47M shares, 0.5x its 50-day average of 4.90M — lighter than usual.
- Price is +27.4% vs its 50-day average ($0.30) and -4.8% vs its 200-day average ($0.41).
- 52-week range $0.20–$2.37; today's close sits at 9% of that range, 83.6% below the 52-week high.
Oct 2, 2026 — MREO jumps 3.5% to $0.38
- Closed at $0.38, +3.54% vs the prior close of $0.37. Day range $0.36–$0.39, opened at $0.38.
- Volume was 880.40K shares, 0.2x its 50-day average of 4.90M — lighter than usual.
- Price is +25.6% vs its 50-day average ($0.30) and -8.6% vs its 200-day average ($0.42).
- 52-week range $0.20–$2.37; today's close sits at 8% of that range, 84.0% below the 52-week high.
MREO latest news & SEC filings
Every SEC filing by or about MREO in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Aug 19, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 3.01 — Stock exchange listing notice or transfer of listing.
Aug 14, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 11, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $0 (prior year $500.00K) (-100.0% vs Jun 30, 2025)
- Net income: -$7.00M (prior year -$14.62M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.01 (prior year -$0.02) (loss narrowed vs Jun 30, 2025)
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 11, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.01 — Signed a material agreement.
- Item 7.01 — Released information under Regulation FD (e.g. a presentation or press release).
Things to know before you trade MREO
- Last results release: Aug 11, 2026 (8-K Item 2.02). Previous ones: Mar 19, 2026, Nov 10, 2025, Aug 12, 2025. Based on that rhythm, the next report is likely around Nov 10, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.72% (largest 10.0%). That is a volatile stock.
- Liquidity: about 1.62M shares (≈$489.54K) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.30 vs a range of $0.20–$2.37 (5% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 8-K Aug 19, 2026; 10-Q Aug 11, 2026; 8-K Aug 11, 2026.
- Share count: 798.45M shares outstanding (Aug 7, 2026), +0.4% vs a year earlier.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
MREO market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.30 | 0.31 | 0.29 | 0.30 | 720.54K |
| Oct 15, 2026 | 0.30 | 0.32 | 0.30 | 0.31 | 529.30K |
| Oct 14, 2026 | 0.31 | 0.32 | 0.30 | 0.31 | 890.20K |
| Oct 13, 2026 | 0.31 | 0.32 | 0.30 | 0.32 | 1.27M |
| Oct 12, 2026 | 0.35 | 0.36 | 0.31 | 0.31 | 1.33M |
| Oct 9, 2026 | 0.38 | 0.39 | 0.34 | 0.35 | 1.22M |
| Oct 8, 2026 | 0.35 | 0.38 | 0.34 | 0.38 | 1.06M |
| Oct 7, 2026 | 0.35 | 0.37 | 0.35 | 0.35 | 1.13M |
| Oct 6, 2026 | 0.40 | 0.40 | 0.35 | 0.35 | 1.27M |
| Oct 5, 2026 | 0.37 | 0.40 | 0.36 | 0.39 | 2.47M |
| Oct 2, 2026 | 0.38 | 0.39 | 0.36 | 0.38 | 880.40K |
| Oct 1, 2026 | 0.40 | 0.40 | 0.36 | 0.37 | 1.60M |
| Sep 30, 2026 | 0.37 | 0.42 | 0.37 | 0.40 | 3.07M |
| Sep 29, 2026 | 0.37 | 0.39 | 0.36 | 0.37 | 1.55M |
| Sep 28, 2026 | 0.37 | 0.38 | 0.35 | 0.37 | 1.74M |
| Sep 25, 2026 | 0.33 | 0.37 | 0.33 | 0.37 | 2.10M |
| Sep 24, 2026 | 0.34 | 0.35 | 0.32 | 0.34 | 1.31M |
| Sep 23, 2026 | 0.32 | 0.37 | 0.31 | 0.34 | 3.92M |
| Sep 22, 2026 | 0.29 | 0.32 | 0.29 | 0.32 | 2.32M |
| Sep 21, 2026 | 0.30 | 0.31 | 0.29 | 0.29 | 1.93M |
About Mereo BioPharma
Mereo BioPharma (MREO) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in LONDON. State of incorporation: United Kingdom. Fiscal year ends December 31. SEC CIK 1719714.
MREO board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Jeremy Bender | Director | Feb 27, 2026 |
| Anders Ekblom | Director | Feb 27, 2026 |
| Pierre Jacquet | Director | Feb 27, 2026 |
| Annalisa Jenkins | Director | Feb 27, 2026 |
| Deepika Pakianathan | Director | Feb 27, 2026 |
| Denise Scots-Knight | Chief Executive Officer | Feb 2, 2026 |
| Daniel Shames | Director | Feb 27, 2026 |
| Michael S Wyzga | Director | Feb 27, 2026 |
| Marc J Yoskowitz | Director | Feb 27, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Christine Ann Fox | Chief Financial Officer | Feb 2, 2026 |
| Alexandra Hughes-Wilson | See Remarks | Feb 2, 2026 |
| John A. Lewicki | Chief Scientific Officer | Feb 2, 2026 |
| Denise Scots-Knight | Chief Executive Officer | Feb 2, 2026 |
| Charles Sermon | General Counsel | Feb 2, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
MREO financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $500.00K | $-41.88M | -0.05 | $-30.97M |
| Dec 31, 2024 | $0 | $-43.25M | -0.06 | $-32.83M |
| Dec 31, 2023 | $10.00M | $-29.47M | -0.04 | $-21.13M |
| Dec 31, 2022 | $0 | $-42.22M | -0.07 | $-48.82M |
Latest balance sheet: total assets $34.71M, total liabilities $6.06M, cash $30.12M (as of Jun 30, 2026).
MREO earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 11, 2026 | 8-K Item 2.02 (results) | $0.31 |
| Mar 19, 2026 | 8-K Item 2.02 (results) | $0.36 |
| Nov 10, 2025 | 8-K Item 2.02 (results) | $1.77 |
| Aug 12, 2025 | 8-K Item 2.02 (results) | $1.66 |
| May 13, 2025 | 8-K Item 2.02 (results) | $2.32 |
| Mar 26, 2025 | 8-K Item 2.02 (results) | $2.37 |
| Nov 12, 2024 | 8-K Item 2.02 (results) | $4.10 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 15, 2024 | 8-K Item 2.02 (results) | — |
| Mar 27, 2024 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on MREO
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.